Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arbutus Biopharma

3.55
+0.14004.11%
Post-market: 3.550.00000.00%16:01 EDT
Volume:1.12M
Turnover:3.97M
Market Cap:679.75M
PE:-9.34
High:3.62
Open:3.36
Low:3.36
Close:3.41
Loading ...

Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement

MT Newswires Live
·
03 Mar

Genevant: Seeking Monetary Relief, Injunctions Against Spikevax &, Where Applicable, Additional Products That Moderna Represented Use Same Lnp Tech

THOMSON REUTERS
·
03 Mar

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

THOMSON REUTERS
·
03 Mar

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

GlobeNewswire
·
03 Mar

Positive Outlook on Arbutus Biopharma Amid Strategic Focus and Legal Developments

TIPRANKS
·
27 Feb

Arbutus Biopharma Names Lindsay Androski CEO, Overhauls Board

MT Newswires Live
·
25 Feb

Arbutus Biopharma's Entire Board Replaced as New CEO Steps In

Dow Jones
·
25 Feb

Arbutus Biopharma appoints Lindsay Androski as CEO

TIPRANKS
·
25 Feb

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

THOMSON REUTERS
·
25 Feb

Arbutus Biopharma Corp - Appoints Lindsay Androski as CEO

THOMSON REUTERS
·
25 Feb

Arbutus Biopharma Corp - All Existing Arbutus Board Members Step Down

THOMSON REUTERS
·
25 Feb

Arbutus Biopharma Corp - to Pause Investor Meetings During Strategic Review

THOMSON REUTERS
·
25 Feb

Press Release: Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Dow Jones
·
25 Feb

Arbutus Biopharma Corp expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
24 Feb

Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy?

Insider Monkey
·
12 Feb

Arbutus Biopharma Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
21 Jan

Positive Outlook for Arbutus Biopharma: Promising Developments and Financial Strength Justify Buy Rating

TIPRANKS
·
21 Jan

Jim Cramer on Arbutus Biopharma Corporation (ABUS): ‘It Loses Money’

Insider Monkey
·
17 Jan

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?

Zacks
·
15 Jan

Arbutus Biopharma: Strategic Advancements and Strong Financial Outlook Support Buy Rating

TIPRANKS
·
14 Jan